Company / SG&A per Share
ADMA Biologics, Inc. SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$0.39
FY2025
5-year range
$0.22 / $0.41
FY2021-FY2025
Trend
+18.0%
vs FY2024
Sector context
#181 of 210
Health Care
What the data says
ADMA Biologics, Inc.'s sg&a per share of $0.39 is lower than 86% of companies in the Health Care sector (FY2025). SG&A per Share has increased for 3 consecutive years, from $0.22 in FY2022 to $0.39 in FY2025.
Based on SEC 10-K filings.
0.39 in FY2025 with a 5-year CAGR of -8.1%.
Increased from $0.27 to $0.39 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +20.9%
- 5-Year CAGR
- -8.1%
- 10-Year CAGR
- -
Sector benchmark
Top 14% in Health CareTop 14% of 210This company $0.39 Sector average $29.50
▼
-98.7% below sector average
Key checks
Key Insights
- ADMA Biologics, Inc.'s sg&a per share has grown for 3 consecutive years.
- In FY2025, sg&a per share increased 18.0% year-over-year.
- Ranks #181 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.39 | +18.0% |
| FY2024 | $0.33 | +23.2% |
| FY2023 | $0.27 | +21.5% |
| FY2022 | $0.22 | -46.4% |
| FY2021 | $0.41 | -30.8% |
| FY2020 | $0.59 | +5.7% |
| FY2019 | $0.56 | -8.8% |
| FY2018 | $0.61 | -7.0% |
| FY2017 | $0.66 | -16.9% |
| FY2016 | $0.79 | +52.7% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026